Skip to main content

Table 1 Summary table of analysis populations for selected autoantibodies and outcomes

From: Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

Biomarker

Baseline requirement

Placebo (N = 105)

Baricitinib 2 mg (N = 105)

Baricitinib 4 mg (N = 104)

Anti-dsDNA

≥30 IU/mL

51 (48.6)

56 (53.3)

53 (51.0)

IgG

No requirement

101 (96.2)

99 (94.3)

96 (92.3)

C3

<90 mg/dL

30 (28.6)

30 (28.6)

34 (32.7)

C4

<10 mg/dL

15 (14.3)

26 (24.8)

15 (14.4)

Anti-Sm

≥30 IU/mL

12 (11.47)

7 (6.67)

9 (8.7)

aCL IgM

>12 MPL

20 (19.0)

22 (20.9)

22 (21.2)

aCL IgG

>14 GPL

10 (9.5)

10 (9.5)

5 (4.8)

aCL IgA

>11 APL

4 (3.8)

6 (5.7)

1 (1.0)

Anti-RNP

≥30 IU/mL

28 (26.7)

21 (20.0)

28 (27.0)

Anti-SSA

>20 IU/mL

35 (33.3)

27 (25.7)

27 (26.0)

Anti-SSB

>20 IU/mL

15 (14.3)

15 (14.3)

16 (15.3)

  1. Values are N-observed (N-observed % of N)
  2. APL/GPL/MPL arbitrary units for IgA, IgG, and IgM isotypes, respectively, C component, dsDNA double-stranded deoxyribonucleic acid, Ig immunoglobulin, Sm Smith, RNP ribonucleoproteins, SS Sjögren’s syndrome-related antigen, IU international unit